Alzheimer's drug SPG302 safety study ends early
NCT ID NCT06833281
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aimed to check the long-term safety and effects of a daily pill called SPG302 in people with mild-to-moderate Alzheimer's disease. It included 12 participants who had already been in a previous SPG302 study. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Flinders Medical Center
Adelaide, South Australia, 5000, Australia
-
St. Vincent's Hospital
Sydney, New South Wales, 2010, Australia